New Discoveries on Exosome Related Research
- Dendritic cell-derived exosomes (Dex), with surface expression of MHC-peptide complexes, are able to interact with immune cells. Having conducted in advanced malignancies, these nanometer-sized Dexs are able to mediate T and NK cell-based immune response in patients as a feasible and safe immunotherapy for cancer. (The Journal of Clinical Investigation,2016)
- Tumor derived exosomes (TDEs) carry epithelial mesenchymal transition inducers to invade organ-specific cells and induce organotropic metastasis through stromal remodeling and pre-metastatic niche formation. Pharmacological agents targeting TDE biogenesis, secretion and function, such as heparanase/ syndecan-1 axis, may exert anti-metastatic activity. (Trends in Pharmacological Sciences,2016)
- Exosome-transmitted IncARSR, by acting as a competing endogenous RNA, can induce sunitinib resistance in renal cancer. IncARSR competitively binds miR-34/miR-449 to facilitate AXL and c-MET expression in renal cell carcinoma and promote sunitinib resistance. Thus, IncARSR may be a potential therapeutic target to restore drug sensitivity. (Cancer Cell,2016)
Tumor-derived Exosomes in Tumor Microenvironment
(Click to see your products of interest) |
| Eight Product Categories and 770+ Products |
|
|
|
| References |
Pitt, JM., et.al. (2016). The Journal of Clinical Investigation. DOI:10.1172/JCI81137
Syn, N., et.al. (2016). Trends in Pharmacological Sciences. DOI:10.1016/j.tips.2016.04.006
Qu, L., et. al. (2016). Cancer Cell. DOI:10.1016/j.ccell.2016.03.004 |
|
